innerbuddies gut microbiome testing

Gut Microbiome and Gestational Diabetes: Pregnancy Blood Sugar Explained

Gestational diabetes (GDM) affects how your body handles glucose during pregnancy. While insulin resistance is a central driver, research increasingly suggests that your gut microbiome—the trillions of microbes living in your intestines—can influence blood sugar regulation. These microbes help shape digestion, energy balance, and the body’s inflammatory response, all of which can affect how efficiently glucose is processed.

During pregnancy, hormone shifts and changes in diet can alter the gut microbiome’s composition and activity. In some people, certain microbiome patterns are associated with higher inflammation and less favorable metabolic signaling, which may contribute to insulin resistance and higher glucose levels. The gut ecosystem also produces metabolites, such as short-chain fatty acids (SCFAs), that support gut barrier function and help regulate immune pathways linked to glucose control.

The good news: microbiome-supporting habits may offer an added layer of support alongside prenatal care and nutrition guidance. Focusing on fiber-rich foods, gut-friendly fats, and fermented options (as appropriate for pregnancy tolerance) can help promote a microbiome that supports healthier glucose metabolism. In the sections ahead, we’ll break down what researchers have found and share practical, pregnancy-safe ways to nurture your microbiome to support steadier blood sugar.

Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gestational diabetes

Gestational diabetes (GDM) arises from insulin resistance during pregnancy, and growing evidence suggests the gut microbiome helps shape how the body regulates glucose. Differences in microbial diversity and the balance of beneficial versus less favorable bacteria, along with altered microbial metabolism, can influence gut barrier function, inflammation, and insulin sensitivity during pregnancy. Diets rich in fiber from vegetables, legumes, whole grains (when tolerated), nuts, and seeds may support beneficial microbes and complement medical care by promoting healthier glucose regulation.

GDM-associated microbiome shifts often include reduced diversity and changes in specific taxa, with lower levels of beneficial microbes such as Akkermansia and Faecalibacterium and higher levels of certain pro-inflammatory groups. Microbial metabolites like short-chain fatty acids (SCFAs) and bile-acid signaling play key roles in glucose handling and inflammation. Dysbiosis can also increase gut permeability, contributing to systemic inflammation and worsened insulin resistance.

Testing the microbiome can help identify an individual’s gut ecosystem patterns related to insulin resistance and guide personalized nutrition—emphasizing fiber-rich, minimally processed foods and targeted prebiotics under clinician guidance. InnerBuddies frames its testing as a way to contextualize gut–metabolism signals and support practical dietary and lifestyle choices during pregnancy, without replacing standard GDM management.

  • Reduced gut microbial diversity in gestational diabetes, with lower abundance of protective taxa such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Butyrivibrio spp., Bifidobacterium spp., Subdoligranulum spp., and Ruminococcus bromii.
  • Elevated levels of pro-inflammatory/insulin-resistance-associated taxa in GDM, including Streptococcus spp., Escherichia/Shigella, Enterococcus, Bilophila wadsworthia, Bacteroides spp., Alistipes spp., and Dialister.
  • Altered microbial metabolism with reduced production of short-chain fatty acids (butyrate and propionate), which can compromise gut barrier integrity and worsen insulin sensitivity.
  • Dysbiosis may increase intestinal permeability and promote low-grade inflammation, contributing to impaired glucose regulation during pregnancy.
  • Microbial changes alter bile acid metabolism, affecting signaling through FXR and TGR5 and influencing insulin sensitivity and glucose handling.
  • Fiber-rich, minimally processed diets can support SCFA-producing and beneficial taxa (e.g., Bifidobacterium, Faecalibacterium, Roseburia) to help improve glucose control in GDM.
  • Microbiome testing can guide personalized nutrition by indicating whether the gut ecosystem trends toward insulin-resistance-associated patterns and by informing targeted dietary choices.
Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Pregnancy-related

Gestational diabetes (GDM) is a form of high blood sugar that develops during pregnancy, usually due to insulin resistance—meaning the body has trouble using insulin effectively to keep glucose levels in a healthy range. While genetics and pregnancy-related hormone changes play major roles, research is increasingly pointing to the gut microbiome (the community of microbes living in your intestines) as another factor that may influence how your body regulates glucose. Because the gut microbiome affects digestion, inflammation, and how nutrients are processed, it may help shape metabolic health during pregnancy.

Studies suggest that women who develop GDM may have different gut microbiome patterns compared with those who maintain normal glucose levels. These differences can involve microbial diversity, the balance of beneficial versus potentially less favorable bacteria, and how efficiently microbes produce key metabolites such as short-chain fatty acids (SCFAs). SCFAs (including butyrate and propionate) support gut barrier function and may influence insulin sensitivity and glucose metabolism. In GDM, shifts in microbial activity may also contribute to low-grade inflammation, altered gut permeability (“leaky gut”), and changes in the body’s response to carbohydrates—factors that can worsen insulin resistance.

The encouraging news is that gut-friendly habits may support healthier glucose regulation during pregnancy. Diet patterns high in fiber—such as vegetables, legumes, whole grains (when tolerated), nuts, and seeds—generally promote beneficial microbes that produce SCFAs. Prebiotic fibers and minimally processed foods can help “feed” helpful bacteria, while limiting highly refined, ultra-processed foods may reduce microbial dysbiosis and metabolic stress. Alongside medical guidance for GDM (including blood sugar monitoring and prescribed care), lifestyle strategies that nurture the microbiome—plus appropriate supplementation only when recommended by your clinician—may help improve metabolic outcomes and pregnancy health.

  • Elevated blood sugar readings during pregnancy (often found on screening or routine glucose testing)
  • Increased thirst (polydipsia)
  • Frequent urination (polyuria)
  • Unexplained fatigue or low energy
  • Blurred vision
  • Increased hunger
  • Higher-than-usual glycosuria (glucose in urine, sometimes detected at prenatal visits)
Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gestational diabetes

This information is relevant for pregnant people who have been diagnosed with gestational diabetes (GDM) or who are currently being evaluated after abnormal screening glucose tests. It’s especially helpful for those whose blood sugar readings run high during pregnancy and who want to understand potential gut-microbiome influences on insulin resistance, inflammation, and glucose handling. Because GDM is tied to pregnancy-related hormone changes and metabolic stress, readers looking for complementary, gut-focused strategies alongside standard medical care will benefit most.

It also applies to individuals experiencing common GDM symptoms such as increased thirst, frequent urination, unexplained fatigue, blurred vision, increased hunger, or elevated glucose in urine noted at prenatal visits. If these symptoms overlap with lab results showing elevated blood sugar, the content can help explain why gut microbial composition and activity (including microbial diversity and metabolite production like short-chain fatty acids) may differ in GDM and how those shifts could relate to insulin sensitivity and metabolic regulation.

This is relevant for readers who are interested in evidence-informed lifestyle habits that may support healthier glucose control during pregnancy—particularly those motivated to improve diet quality by increasing fiber-rich, minimally processed foods (vegetables, legumes, whole grains when tolerated, nuts, and seeds) and using prebiotic-rich options that help beneficial microbes thrive. It’s also for people who want clarity on how gut-focused nutrition may work as an adjunct to clinician-directed management (monitoring, diet recommendations, and any prescribed medication) and when supplementation should only be considered with medical guidance.

Gestational diabetes mellitus (GDM) is a relatively common pregnancy complication worldwide, occurring in roughly 5–14% of pregnancies depending on the population studied and the diagnostic criteria used. In many high-income countries, prevalence is often cited around 6–8%, while some regions—especially where rates of overweight and type 2 diabetes are higher—report closer to 10% or more. Many cases are detected through routine screening rather than obvious symptoms, which is why prevalence can vary widely between studies.

Because GDM is characterized by elevated blood glucose identified during pregnancy, its “symptom pattern” is often subtle. Commonly reported issues include increased thirst (polydipsia), frequent urination (polyuria), fatigue, blurred vision, and increased hunger, along with glycosuria (glucose in the urine) noted at prenatal visits. However, a significant fraction of pregnant people with GDM have mild or no noticeable symptoms, making prevalence estimates rely heavily on standardized screening such as oral glucose tolerance testing.

Risk also differs across groups, which helps explain why prevalence can range from about 1 in 20 to more than 1 in 7 pregnancies. Factors like prior GDM, a family history of diabetes, higher pre-pregnancy body weight, older maternal age, and certain ethnic backgrounds are linked to higher rates. As screening becomes more widespread and diagnostic thresholds evolve, observed prevalence tends to increase—consistent with the fact that GDM is a major contributor to the broader burden of glucose intolerance in pregnancy.

Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Gestational Diabetes: How Your Microbiome May Affect Pregnancy Blood Sugar

Gestational diabetes (GDM) involves insulin resistance during pregnancy, and emerging research suggests the gut microbiome may help influence how well the body regulates glucose. The gut microbes help shape metabolism through effects on digestion, immune signaling, and inflammation—processes that are especially relevant in pregnancy when hormonal changes can alter insulin sensitivity. In women who develop GDM, studies often find differences in gut microbial diversity and in the balance of beneficial versus less favorable bacterial groups compared with those who maintain normal blood sugar.

Microbiome-driven changes may also affect glucose control through microbial metabolites, particularly short-chain fatty acids (SCFAs) such as butyrate and propionate. SCFAs support gut barrier integrity and can modulate insulin sensitivity and glucose metabolism. When microbial activity shifts in GDM, SCFA production and gut barrier function may be altered, potentially contributing to low-grade inflammation and increased gut permeability (“leaky gut”). These changes can worsen metabolic stress and make it harder for the body to respond to carbohydrates effectively.

Clinically, GDM often presents with elevated blood sugar on screening and may be accompanied by symptoms like increased thirst, frequent urination, fatigue, blurred vision, and higher glucose in urine. Because diet strongly influences gut microbial composition and metabolite output, gut-supportive eating patterns—such as higher fiber intake from vegetables, legumes, nuts, and seeds, plus prebiotic foods that feed beneficial bacteria—may help promote a microbiome profile associated with healthier glucose regulation. While medical management is essential, nurturing the gut ecosystem through minimally processed, fiber-rich choices (and any supplementation only under clinician guidance) may complement standard GDM care by supporting metabolic and inflammatory balance.

Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Gestational diabetes

  • Altered gut microbial composition and reduced diversity can shift metabolic signaling toward a more insulin-resistant state, changing the balance of beneficial vs. pro-inflammatory bacterial groups during pregnancy.
  • Microbial metabolites (especially short-chain fatty acids like butyrate and propionate) can modulate glucose homeostasis by improving insulin sensitivity, supporting GLP-1–mediated incretin signaling, and influencing hepatic and peripheral glucose uptake.
  • Gut barrier integrity may be compromised when dysbiosis alters mucus and tight-junction function, increasing gut permeability and enabling microbial components to drive low-grade inflammation that worsens insulin resistance (systemic inflammation).
  • Immune and inflammatory pathway modulation: the microbiome influences immune tone (e.g., Treg/Th17 balance) and cytokine production, which can affect insulin signaling and promote metabolic dysfunction when dysregulated.
  • Bile acid metabolism: gut microbes transform primary into secondary bile acids that act as signaling molecules (via receptors like FXR/TGR5) to regulate insulin sensitivity, energy expenditure, and glucose control.
  • Carbohydrate fermentation and nutrient absorption: shifts in microbial carbohydrate metabolism and fermentation efficiency can change how quickly and how much glucose is made available, impacting post-meal glucose excursions.

Gestational diabetes (GDM) is strongly tied to insulin resistance during pregnancy, and the gut microbiome may influence how effectively the body regulates glucose. In many studies, people who develop GDM show differences in gut microbial diversity and in the balance of bacterial groups compared with those who maintain normal blood sugar. These shifts can alter metabolic signaling by affecting digestion, immune activity, and inflammation—pathways that are especially sensitive to pregnancy-related hormonal changes. When dysbiosis tilts the ecosystem toward more pro-inflammatory potential, insulin sensitivity can worsen and glucose tolerance may deteriorate.

Microbial metabolites provide one way the gut may affect glucose control. As gut bacteria ferment dietary fibers, they generate short-chain fatty acids (SCFAs) such as butyrate and propionate, which help support gut barrier integrity and can modulate glucose metabolism. SCFAs may improve insulin sensitivity and support incretin-related signaling (including GLP-1 activity), helping the body regulate post-meal blood sugar. If microbial function shifts in GDM—reducing beneficial SCFA output or altering fermentation patterns—metabolic regulation may be impaired, contributing to larger glucose excursions after carbohydrates.

Another key mechanism involves gut barrier integrity and host immune signaling. Dysbiosis can disrupt mucus and tight-junction function, increasing intestinal permeability and allowing microbial components to trigger low-grade systemic inflammation. This inflammatory signaling can interfere with insulin pathways and promote further metabolic dysfunction. In addition, gut microbes reshape bile acid profiles through conversion of primary to secondary bile acids; these bile acids act as signaling molecules through receptors such as FXR and TGR5, influencing insulin sensitivity and glucose handling. Together, altered microbial composition, metabolite changes, barrier effects, and immune/bile-acid signaling can create an environment that makes it harder for the body to maintain healthy glucose regulation during pregnancy.

Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

Gestational diabetes (GDM) has been associated with gut microbiome shifts that often include reduced overall diversity and an altered balance between bacterial groups compared with pregnancies that maintain normal glucose tolerance. These compositional changes are thought to reflect how pregnancy hormones, diet, and metabolic stress interact with the microbial ecosystem, potentially steering microbial communities toward a more pro-inflammatory metabolic environment. As dysbiosis develops, it may affect key host pathways involved in glucose handling—through changes in microbial signaling to the immune system and effects on digestion-related processes that influence nutrient absorption and metabolic tone.

A prominent functional theme in GDM research is altered production of microbial metabolites, especially short-chain fatty acids (SCFAs) such as butyrate and propionate. SCFAs are generated when gut bacteria ferment dietary fibers and help maintain gut barrier integrity while also influencing insulin sensitivity and glucose metabolism. If the microbiome’s fermentative capacity or the types of bacteria driving fiber breakdown shift during GDM, SCFA output and downstream metabolic signaling (including pathways linked to incretin function) may be less favorable, contributing to larger post-meal glucose excursions and impaired glucose regulation.

Another mechanism frequently discussed is increased intestinal permeability driven by disrupted barrier-supporting microbial activity, which can allow microbial components to promote low-grade systemic inflammation. In parallel, changes in gut microbial metabolism of bile acids can modify signaling through bile-acid receptors involved in metabolic regulation, including effects on insulin sensitivity. Together, these patterns—community imbalance, altered SCFA and bile-acid signaling, and barrier/immune disruption—can create a cycle that worsens insulin resistance during pregnancy and makes carbohydrate handling more difficult.


Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Butyrivibrio spp.
  • Bifidobacterium spp.
  • Subdoligranulum spp.
  • Ruminococcus bromii


Elevated / overrepresented taxa

  • Streptococcus spp.
  • Lactobacillus spp.
  • Escherichia/Shigella
  • Enterococcus spp.
  • Bacteroides spp.
  • Alistipes spp.
  • Dialister spp.
  • Bilophila wadsworthia


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis (butyrate/propionate) via microbial fermentation of dietary fibers
  • Glucose homeostasis signaling through microbial metabolites and incretin-related pathways (gut–brain/gut–pancreas signaling)
  • Intestinal barrier integrity and epithelial tight-junction regulation influenced by microbial metabolites (e.g., SCFAs)
  • Regulation of low-grade inflammation via microbial component translocation (pattern-recognition receptor/TLR–NF-κB signaling) driven by increased intestinal permeability
  • Bile acid metabolism and secondary bile acid biosynthesis influencing FXR/TGR5 signaling and insulin sensitivity
  • Amino-acid and energy metabolism shifts affecting oxidative stress and metabolic inflammation (e.g., altered proteolysis/fermentation balance)
  • Gut microbial carbohydrate fermentation and polysaccharide utilization pathways that shape postprandial glucose excursions
  • Microbial modulation of gut immune pathways that influence systemic metabolic tone during pregnancy


Diversity note

In gestational diabetes (GDM), studies frequently report a shift away from a more diverse, resilient gut microbial community. Compared with pregnancies that maintain normal glucose tolerance, women with GDM often show reduced overall microbial diversity and a different balance of bacterial groups, suggesting dysbiosis rather than a single “pathogenic” organism. These compositional changes are thought to reflect how pregnancy-related hormone shifts, diet, and evolving insulin resistance interact to reshape the intestinal ecosystem during gestation.

Beyond diversity, the altered community structure in GDM is commonly linked to functional differences in how microbes process nutrients. When the microbial balance shifts, the gut’s capacity to ferment dietary fibers and generate protective metabolites—especially short-chain fatty acids (SCFAs) like butyrate and propionate—may be less optimal. Because SCFAs support gut barrier integrity and help regulate insulin sensitivity and glucose metabolism, reduced or altered SCFA-related signaling can contribute to poorer post-meal glucose control.

In addition, dysbiosis in GDM may coincide with changes that affect intestinal barrier function and inflammatory tone. A less favorable microbial balance can reduce barrier-supporting activity and increase permeability signals, allowing microbial components to promote low-grade systemic inflammation—conditions that can further worsen insulin resistance during pregnancy. Together, these diversity and ecosystem-level changes can help explain why microbiome composition in GDM often tracks with impaired metabolic regulation.


Shop Gut Microbiome Testing for Gestational Diabetes Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    For gestational diabetes, generic “gut support” approaches often fall short because GDM is not just a matter of low or high bacterial count—it’s a dynamic shift in microbiome structure and function that occurs alongside pregnancy hormones, changing diet patterns, and evolving insulin resistance. Many broad recommendations (e.g., generic probiotic use or general detox/cleansing trends) don’t account for the specific microbial dysbiosis and altered metabolic output seen in GDM, such as reduced diversity and a less favorable balance of bacterial groups linked to glucose regulation.

    Another reason generic solutions fail is that the most relevant microbiome effects in GDM are functional, not merely compositional. In particular, research highlights altered short-chain fatty acid (SCFA) production (e.g., butyrate and propionate) and changes in gut barrier integrity and bile-acid signaling. A one-size-fits-all probiotic may not reliably enhance the ability to ferment fiber into SCFAs or may not produce the right downstream signaling for insulin sensitivity, especially if the underlying diet doesn’t provide sufficient substrates (like diverse, fermentable fibers) to drive those pathways.

    Finally, timing and personalization matter: pregnancy creates rapidly changing physiology, and gut responses to interventions can be inconsistent depending on baseline diet, glucose patterns, microbiome starting point, and medication use (such as insulin or metformin, when applicable). Generic products may also introduce strains that don’t persist in the gut or that don’t address contributors to low-grade inflammation (like increased intestinal permeability). Without clinician-guided alignment to nutritional needs and glucose targets, “standard” gut interventions can end up neutral at best, or may distract from evidence-based GDM management.

  • Common mistakes

    • Using a one-size-fits-all probiotic without matching strains to GDM-relevant functions (e.g., enhancing SCFA production such as butyrate/propionate and supporting barrier integrity), so the intervention won’t shift the metabolic output that matters.
    • Over-focusing on “increasing diversity” or adding microbes while ignoring functional deficits documented in GDM—especially altered fiber fermentation, SCFA signaling, and bile-acid–receptor pathways that influence insulin sensitivity and glucose excursions.
    • Assuming probiotics alone can compensate for substrate limitations by not adjusting dietary fermentable fibers (and overall carbohydrate quality), even though SCFAs depend on available fiber for fermentation.
    • Ignoring that GDM dysbiosis is dynamic across pregnancy and worsens with evolving insulin resistance, leading to mistimed interventions that don’t align with changes in physiology and diet.
    • Not accounting for baseline differences (starting microbiome composition/function) and individual glucose patterns, resulting in inconsistent responses because the same product can be neutral for some and unhelpful for others.
    • Failing to consider barrier/immune mechanisms (increased intestinal permeability and low-grade inflammation), which generic “gut support” products may not address—so inflammation-linked insulin resistance persists.
    • Recommending generic detox/cleansing trends or overly restrictive diets that can reduce beneficial microbes and fermentable substrates, potentially worsening SCFA output and metabolic stability.
    • Not coordinating with standard GDM care and medication context (e.g., insulin or metformin when applicable), which can influence gut ecology and metabolite production—making uncoupled supplements less effective.

What to do

  • General support strategies

    Gestational diabetes (GDM) is closely tied to insulin resistance during pregnancy, and the gut microbiome appears to influence how well the body manages glucose. Gut microbes help regulate metabolism through effects on digestion, immune signaling, and low-grade inflammation—pathways that can shift during pregnancy as hormones change. In GDM, research commonly shows differences in microbial diversity and the balance of bacterial groups compared with pregnancies that maintain normal blood sugar, suggesting that supporting a healthier gut ecosystem may complement standard prenatal care.

    One promising mechanism involves microbial metabolites, especially short-chain fatty acids (SCFAs) like butyrate and propionate. SCFAs support gut barrier integrity and can modulate insulin sensitivity and glucose metabolism. When the microbiome shifts, SCFA production and barrier function may change, potentially contributing to increased gut permeability and inflammatory stress—factors that can worsen metabolic control. Supporting the microbiome to favor SCFA-producing communities may therefore help create a more metabolically supportive intestinal environment during pregnancy.

    Diet is a primary lever for microbiome support in GDM, since it strongly shapes bacterial composition and metabolite output. Emphasizing minimally processed, fiber-rich foods—such as vegetables, legumes, nuts, seeds, and whole grains—helps provide prebiotics that feed beneficial microbes. Including a variety of plant fibers and prebiotic-rich ingredients can encourage a more favorable microbial balance, while maintaining carbohydrate choices and meal patterns in line with individualized medical guidance. Any supplements should only be used under clinician direction, but food-first strategies that promote microbial health may help support glucose regulation alongside conventional GDM management.

  • Lifestyle recommendations

    • Follow a gestational-diabetes–appropriate meal plan emphasizing high-fiber, minimally processed foods (vegetables, legumes, nuts, seeds, whole grains) to support healthier gut microbiome activity and glucose control.
    • Prioritize prebiotic fibers daily (e.g., legumes, oats, barley, bananas slightly underripe, onions, garlic, leeks) to help beneficial bacteria produce protective SCFAs.
    • Choose carbohydrate quality and timing carefully: pair carbs with lean protein and healthy fats, and spread carbohydrate intake across meals/snacks to reduce glucose spikes.
    • Engage in regular pregnancy-safe physical activity (e.g., brisk walking after meals or as advised by your clinician) to improve insulin sensitivity and metabolic regulation.
    • Aim for adequate hydration and good sleep, and manage stress (e.g., mindfulness, gentle yoga, breathing exercises), since these can influence inflammation and metabolic health during pregnancy.
    • Avoid smoking and limit alcohol (ideally none in pregnancy), and use antibiotics or probiotic/supplement products only under clinician guidance to prevent unintended disruption of gut balance.

  • Nutrition recommendations

    • Prioritize high-fiber, minimally processed carbohydrates (non-starchy vegetables, legumes, berries, whole grains where tolerated) to support beneficial gut diversity and increase microbial production of SCFAs (e.g., butyrate/propionate) that may improve insulin sensitivity.
    • Emphasize prebiotic-rich foods daily (garlic, onions, leeks, asparagus, chicory root/ground inulin, oats, bananas that are less ripe) to feed good gut bacteria and promote a healthier glycemic profile.
    • Include fermented foods in moderation (plain yogurt/kefir, sauerkraut, kimchi, tempeh) for probiotic support that may help reduce gut-driven inflammation and support glucose regulation—choose pasteurized options in pregnancy.
    • Choose healthy fats and adequate protein at meals (olive oil, avocado, nuts/seeds, eggs, fish, tofu/tempeh) to blunt post-meal glucose spikes and help maintain a gut-friendly metabolic environment.
    • Aim for low–glycemic load meal structure: pair carbohydrates with fiber, protein, and fat; avoid sugar-sweetened beverages and refined carbs; spread carbs across meals/snacks to improve post-prandial glucose control.
    • Support gut barrier function with micronutrient- and polyphenol-rich foods (berries, leafy greens, extra-virgin olive oil, cocoa, spices like cinnamon/ginger) to help reduce low-grade inflammation relevant to GDM.
    • Stay consistent with hydration and consider clinician-approved supplementation only if needed (e.g., vitamin D, omega-3) rather than starting gut-targeted supplements without medical guidance in pregnancy.

  • Supplement considerations

    For gestational diabetes (GDM), supplement choices should be considered as add-ons to standard medical care (dietary therapy, glucose monitoring, and insulin or other medications if needed). Because the gut microbiome can influence insulin sensitivity and inflammation—partly through microbial metabolites such as short-chain fatty acids (SCFAs)—supplements that support microbial balance and gut barrier function may be relevant. In particular, fibers/precursors with prebiotic effects (often found as supplements in products like inulin-type fibers, partially hydrolyzed fibers, or resistant starches) can help beneficial bacteria produce SCFAs that support gut integrity and may help moderate glucose metabolism. However, in pregnancy it’s important to introduce any fermentable fiber gradually to reduce gas or bloating and to ensure it aligns with the individual’s carbohydrate targets set by the care team.

    Probiotics are another supplement category that has attracted interest for GDM, with the goal of improving microbial diversity and shifting the balance toward more metabolically favorable communities. Some studies suggest certain probiotic strains may influence markers related to glucose regulation, but responses can vary widely by strain, dose, and study design. If considering a probiotic in pregnancy, it’s best to choose products with clear strain labeling and evidence for the intended clinical context, and to coordinate with an OB-GYN or registered dietitian—especially if there are risks for immunologic complications or if the individual is already using specific therapies.

    Because microbiome effects are partly mediated by metabolites and inflammation, other supplements sometimes discussed in this space include omega-3 fatty acids (for anti-inflammatory support) and nutrients that influence gut-immune signaling, but these should not replace glucose-lowering treatment. If vitamin D, magnesium, or other micronutrients are being considered, it should ideally be based on bloodwork and clinician guidance to avoid excessive dosing during pregnancy. Overall, the most prudent approach is to prioritize supplement options that have a clear safety profile in pregnancy and a plausible microbiome-related mechanism, while monitoring blood glucose trends and side effects as part of an integrated GDM plan.

  • Retesting / monitoring note

    Gestational diabetes (GDM) is typically diagnosed with glucose testing during pregnancy, and retesting is often recommended to confirm whether glucose regulation has normalized or if additional management is needed. Because hormonal changes in pregnancy can shift insulin sensitivity over time, clinicians may schedule follow-up glucose checks—especially if initial results were borderline, if blood sugar targets are difficult to maintain, or if treatment adjustments occur. Retesting is also commonly used to ensure that ongoing dietary and lifestyle changes (and any prescribed therapy) are achieving adequate glycemic control.

    After delivery, retesting becomes particularly important. Many guidelines recommend postpartum screening for persistent glucose intolerance or progression toward type 2 diabetes, since pregnancy can unmask a lasting metabolic risk. This follow-up testing helps distinguish temporary pregnancy-related insulin resistance from longer-term dysregulation. If the gut microbiome contributes to metabolic control—as research suggests through microbial diversity, gut barrier effects, and metabolite signaling such as short-chain fatty acids (SCFAs)—then postpartum metabolic recovery may also be monitored through these standard clinical tests.

    In parallel with clinical retesting, some patients discuss timing and preparation strategies that support consistent results—such as maintaining usual medication plans as directed and following clinician guidance on meals and fasting requirements before testing. For women aiming to support healthy gut ecology alongside standard GDM care, focusing on fiber-rich, minimally processed foods (vegetables, legumes, nuts, seeds, and other prebiotic sources) may promote beneficial microbial fermentation and SCFA production, which can support gut barrier integrity and help reduce low-grade inflammation that may interfere with glucose regulation. Any supplementation (for example, probiotics or fiber supplements) should be considered only in coordination with the treating clinician, particularly during pregnancy and the immediate postpartum period.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in gestational diabetes because it can reveal whether the mother’s gut microbial ecosystem is shifting toward patterns linked with insulin resistance and impaired glucose regulation. During pregnancy, hormonal changes already influence digestion and immune signaling, and research suggests that differences in microbial diversity and the balance of beneficial versus less favorable bacterial groups may correlate with how effectively the body processes carbohydrates. By identifying these microbiome signatures, testing may help clarify why some individuals develop higher blood sugar despite similar diets or risk factors.

    Microbiome testing can also be informative because gut bacteria produce metabolites—especially short-chain fatty acids (SCFAs) like butyrate and propionate—that support gut barrier integrity and help modulate inflammation and insulin sensitivity. When microbial activity decreases SCFA output or alters the gut barrier environment, it may contribute to low-grade inflammation and increased gut permeability, which can worsen metabolic stress in pregnancy. Testing can therefore provide indirect insight into whether the gut ecosystem is producing metabolite profiles more consistent with healthier glucose control.

    Finally, microbiome results can guide more personalized nutrition and lifestyle strategies that complement standard GDM care. Since diet is one of the strongest levers shaping microbial composition and metabolite production, knowing your baseline microbiome may help clinicians and dietitians prioritize fiber-rich, minimally processed foods and targeted prebiotic options that encourage beneficial bacteria. While gut testing doesn’t replace medical management, it can add a useful layer of individualized context for optimizing the microbiome–glucose relationship during pregnancy.

  • How InnerBuddies helps

    For gestational diabetes, InnerBuddies can help by offering a window into the gut microbiome patterns that may relate to insulin resistance and glucose regulation during pregnancy. Because gut bacteria differ in diversity and in the balance of beneficial versus less favorable groups, the test can provide context about whether your current ecosystem resembles profiles more commonly seen in people who experience elevated blood sugar versus those who maintain normal glucose control. This is especially relevant in pregnancy, when hormonal shifts can already change digestion and immune signaling, potentially influencing how your body responds to carbohydrates.

    InnerBuddies also supports interpretation of gut–metabolism links through the microbiome’s role in producing key metabolites, particularly short-chain fatty acids (SCFAs) like butyrate and propionate. These microbial products help support gut barrier integrity and can modulate inflammation pathways that are tied to insulin sensitivity. By assessing your baseline microbial signals, the test may help clarify whether your microbiome appears optimized for healthy SCFA output and gut barrier function—or whether it may be trending toward patterns associated with higher inflammatory stress, which can worsen glucose control.

    Importantly, InnerBuddies results can be used to personalize nutrition and lifestyle choices that complement standard GDM care. Since diet is one of the strongest drivers of microbial composition, your results can help guide practical next steps—such as emphasizing fiber-rich, minimally processed foods (vegetables, legumes, nuts, seeds) and prioritizing prebiotic options that feed beneficial bacteria—under clinician guidance. While gut testing does not replace medical management, it can add individualized insight to support a gut environment that’s more favorable for metabolic balance throughout pregnancy.

Medical Evidence

  • Scientific evidence level

    2 [weak/emerging but inconsistent]

  • Clinical relevance note

    At present, gut microbiome measurement for gestational diabetes is not validated for real-world clinical utility. While multiple studies suggest statistical associations (and some early-pregnancy predictive signals), reproducibility across cohorts and platforms is limited, effect sizes are not consistently robust, and models have not been sufficiently externally validated or shown to improve clinical decision-making (e.g., better targeting of screening, preventing progression, stratifying therapy, or monitoring response). Even when associations reach statistical significance, residual confounding (diet, BMI/weight gain, medications, gestational timing) and reverse causality during pregnancy make it difficult to conclude the microbiome is a driver rather than a marker.

    Clinically, the most defensible current stance is: the microbiome is biologically plausible in GDM pathophysiology, and observational studies repeatedly implicate alterations in composition/diversity and bile-acid/inflammatory-related pathways; however, causal involvement is unproven and intervention efficacy for GDM endpoints remains uncertain due to heterogeneity and limited trial scale. Consequently, routine microbiome testing to prevent, diagnose, or manage GDM is premature. Future progress would require well-powered prospective cohorts with standardized sampling/assays, rigorous confounder control, external model validation, and RCTs or causal inference designs that demonstrate microbiome modulation leads to clinically meaningful improvements in GDM incidence or glycemic outcomes.

Title Journal Year Link
Gut microbiota and gestational diabetes mellitus: A meta-analysis of case-control studies Frontiers in Endocrinology 2021 View →
Gut microbiota dysbiosis in gestational diabetes mellitus and its association with maternal and neonatal outcomes: A systematic review BMC Pregnancy and Childbirth 2020 View →
The gut microbiome in gestational diabetes mellitus: a systematic review and meta-analysis of 16S rRNA sequencing studies Journal of Diabetes Investigation 2019 View →
Microbiome signatures associated with gestational diabetes mellitus in Chinese women Diabetes Care 2019 View →
Maternal gut microbiota and gestational diabetes mellitus: a prospective study Diabetologia 2012 View →

Frequently Asked Questions

    ¿Qué es la diabetes gestacional (DG) y cómo podría estar involucrado el microbioma intestinal?
    La DG es un nivel alto de azúcar en sangre que se desarrolla durante el embarazo debido a la resistencia a la insulina. Investigaciones sugieren que el microbioma podría influir en la digestión, la inflamación y la sensibilidad a la insulina, afectando así el control de la glucosa.
    ¿Cómo puede afectar el microbioma a la regulación de la glucosa durante el embarazo?
    El microbioma participa en la digestión, la señalización inmunitaria y la inflamación. Cambios en su composición o actividad pueden modificar cómo el cuerpo maneja carbohidratos e insulina.
    ¿Qué son los ácidos grasos de cadena corta (SCFA) y por qué importan en DG?
    Los SCFA son metabolitos producidos por las bacterias intestinales al fermentar fibra. Apoyan la barrera intestinal y pueden influir en la sensibilidad a la insulina y el metabolismo de la glucosa.
    ¿La dieta puede ayudar a apoyar el microbioma durante el embarazo?
    Sí, una dieta rica en fibra (verduras, legumbres, granos integrales si se toleran, frutos secos, semillas) puede favorecer bacterias beneficiosas y la producción de SCFA. Siga las indicaciones médicas para DG.
    ¿Qué alimentos son buenos para la salud intestinal durante el embarazo?
    Enfóquese en alimentos ricos en fibra, prebióticos y alimentos mínimamente procesados; limite los ultraprocesados.
    ¿Qué es una prueba de microbioma y qué puede decirme sobre DG?
    La prueba de microbioma analiza la composición de las bacterias intestinales y su actividad metabólica. Puede dar contexto, pero no es un diagnóstico y no es una prueba única para DG.
    ¿Puede la prueba de microbioma ayudar a gestionar DG?
    Puede ayudar a conversar sobre dieta y estilo de vida que apoyen el microbioma, pero no sustituye la atención estándar de DG (control de glucosa y tratamiento si es necesario).
    ¿Existen bacterias asociadas a una mejor o peor regulación de la glucosa en el embarazo?
    La investigación observa menor diversidad y cambios en ciertos grupos de bacterias; es complejo y no hay una lista simple bueno/malo. La interpretación debe hacerse con un profesional.
    ¿Qué tan común es la DG y quién tiene mayor riesgo?
    Aproximadamente 5–14% de los embarazos; mayor riesgo si hay DG previa, historia familiar de diabetes, mayor peso pregestacional, edad avanzada y ciertas etnias.
    ¿Qué síntomas podrían indicar DG?
    Muchos no tienen síntomas. Signos posibles: sed excesiva, micción frecuente, fatiga, visión borrosa, mayor hambre y glucosa en la orina durante consultas.
    ¿Cómo se diagnostica y se controla la DG?
    El diagnóstico suele basarse en pruebas de cribado (p. ej., prueba de tolerancia a la glucosa) y monitoreo de la glucosa. El manejo incluye atención médica, dieta, actividad física y, a veces, medicación.
    ¿Qué relación hay entre la barrera intestinal y la inflamación en DG?
    La disbiosis puede aumentar la permeabilidad intestinal y la inflamación, lo que puede influir en la señalización de la insulina. Una dieta y estilo de vida que apoyen la barrera intestinal pueden ser útiles.
    ¿Pueden las diferencias del microbioma explicar por qué personas con dietas similares tienen respuestas de glucosa distintas?
    Sí, los microbiomas y sus metabolitos pueden variar entre personas, lo que justifica enfoques personalizados bajo supervisión médica.
    ¿Puede el testing del microbioma guiar elecciones de nutrición o estilo de vida?
    Puede ayudar a discutir la ingesta de fibra y prebióticos; las decisiones deben hacerse con profesionales de la salud y no sustituyen la atención DG.
    ¿Qué papel juega InnerBuddies en DG y salud intestinal?
    InnerBuddies ofrece perspectivas sobre el microbioma que pueden contextualizar la regulación de la glucosa durante el embarazo; los resultados deben utilizarse como complemento a la atención médica.
    ¿Hay riesgos o limitaciones en el test del microbioma durante el embarazo?
    Los tests pueden aportar información, pero no son un diagnóstico y requieren interpretación por expertos. No sustituyen pruebas clínicas.
    ¿Debo tomar suplementos basados en el test del microbioma?
    Solo bajo recomendación de su médico; algunos suplementos pueden influir en la glucosa o interactuar con el embarazo.
    ¿Cómo podría el DG afectar la salud a largo plazo de la madre y el bebé?
    El DG aumenta el riesgo de problemas metabólicos futuros y puede influir en los resultados a corto plazo de la gestación. Hable de esto con su médico.
    ¿Qué papel tienen los ácidos biliares en este contexto?
    El microbioma puede cambiar los perfiles de ácidos biliares, influyendo en el metabolismo y la sensibilidad a la insulina a través de vías de señalización. Es un tema de investigación.
    ¿Qué hacer si estoy preocupada por DG durante la gestación?
    Siga las indicaciones del equipo sanitario, participe en las pruebas de cribado, esté atenta a los síntomas, consuma fibra y hable con su médico sobre la salud intestinal.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -